Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
Publication/Presentation Date
1-1-2015
Abstract
The discovery of BRAF mutation in ~50% of melanomas led to the development of small molecule BRAF inhibitors, including sorafenib, debrafenib, and vemurafenib. Clinical trials have shown these agents to be effective in treatment of metastatic and locally advanced melanoma, increasing overall and progression-free survival. However, some of the most common toxicities associated with BRAF inhibitor therapy include adverse skin events such as rashes, photosensitivity, hyperkeratosis, papillomas, keratoacanthomas, and squamous cell carcinomas. Here, the authors describe 3 patients who developed keratinocytic neoplasms on the eyelid, including invasive squamous carcinoma secondary to vemurafenib. Vigilant screening and a high index of suspicion for eyelid carcinomas are recommended in patients treated with vemurafenib.
Volume
31
Issue
4
First Page
112
Last Page
115
ISSN
1537-2677
Published In/Presented At
Yin, V. T., Wiraszka, T. A., Tetzlaff, M., Curry, J. L., & Esmaeli, B. (2015). Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy. Ophthalmic plastic and reconstructive surgery, 31(4), e112–e115. https://doi.org/10.1097/IOP.0000000000000140
Disciplines
Medicine and Health Sciences
PubMedID
24833447
Department(s)
Department of Medicine
Document Type
Article